|
US4405616A
(en)
*
|
1975-06-19 |
1983-09-20 |
Nelson Research & Development Company |
Penetration enhancers for transdermal drug delivery of systemic agents
|
|
US3989816A
(en)
|
1975-06-19 |
1976-11-02 |
Nelson Research & Development Company |
Vehicle composition containing 1-substituted azacycloheptan-2-ones
|
|
US4316893A
(en)
*
|
1975-06-19 |
1982-02-23 |
Nelson Research & Development Co. |
Vehicle composition containing 1-substituted azacycloalkan-2-ones
|
|
US4557934A
(en)
|
1983-06-21 |
1985-12-10 |
The Procter & Gamble Company |
Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
|
|
US4524008A
(en)
|
1983-12-16 |
1985-06-18 |
E. I. Du Pont De Nemours And Company |
Controlled initiation chromium dioxide synthesis
|
|
US4568343A
(en)
|
1984-10-09 |
1986-02-04 |
Alza Corporation |
Skin permeation enhancer compositions
|
|
US5023252A
(en)
*
|
1985-12-04 |
1991-06-11 |
Conrex Pharmaceutical Corporation |
Transdermal and trans-membrane delivery of drugs
|
|
US4783450A
(en)
|
1987-04-13 |
1988-11-08 |
Warner-Lambert Company |
Use of commercial lecithin as skin penetration enhancer
|
|
US4992445A
(en)
*
|
1987-06-12 |
1991-02-12 |
American Cyanamid Co. |
Transdermal delivery of pharmaceuticals
|
|
US5001139A
(en)
*
|
1987-06-12 |
1991-03-19 |
American Cyanamid Company |
Enchancers for the transdermal flux of nivadipine
|
|
DE3802996A1
(de)
|
1988-02-02 |
1989-08-10 |
Cassella Ag |
Verwendung von 2-oxo-pyrrolidin-1-acetamid zur bestimmung der glomerulaeren filtrationsrate beim menschen
|
|
US5424399A
(en)
*
|
1988-06-28 |
1995-06-13 |
The Children's Medical Center Corporation |
Human CR3α/β heterodimers
|
|
US5149780A
(en)
*
|
1988-10-03 |
1992-09-22 |
The Scripps Research Institute |
Peptides and antibodies that inhibit integrin-ligand binding
|
|
JPH06500555A
(ja)
*
|
1990-08-27 |
1994-01-20 |
カイロン コーポレイション |
病気の処置のためのペプチドの薬物
|
|
US5288854A
(en)
*
|
1990-11-28 |
1994-02-22 |
Center For Blood Research, Inc. |
Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1
|
|
JP3679112B2
(ja)
*
|
1991-10-04 |
2005-08-03 |
アメリカ合衆国 |
細胞接着分子の遮断による眼の炎症の治療
|
|
US6764681B2
(en)
*
|
1991-10-07 |
2004-07-20 |
Biogen, Inc. |
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
|
|
US6162432A
(en)
*
|
1991-10-07 |
2000-12-19 |
Biogen, Inc. |
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
|
|
WO1993017047A1
(en)
*
|
1992-02-28 |
1993-09-02 |
Board Of Regents, The University Of Texas System |
Compositions and methods for the treatment of thermal injury
|
|
US5298492A
(en)
*
|
1992-08-04 |
1994-03-29 |
Schering Corporation |
Diamino acid derivatives as antihypertensives
|
|
AU687755B2
(en)
|
1992-08-21 |
1998-03-05 |
Genentech Inc. |
Method for treating an LFA-1-mediated disorder
|
|
US5397791A
(en)
*
|
1993-08-09 |
1995-03-14 |
Merck & Co., Inc. |
Fibrinogen receptor antagonists
|
|
SI0656348T1
(en)
*
|
1993-12-03 |
2000-08-31 |
F. Hoffmann-La Roche Ag |
Aceric acid derivatives as medicaments
|
|
US5470953A
(en)
*
|
1993-12-23 |
1995-11-28 |
Icos Corporation |
Human β2 integrin α subunit
|
|
US6228383B1
(en)
|
1994-03-03 |
2001-05-08 |
Gs Development Ab |
Use of fatty acid esters as bioadhesive substances
|
|
JPH09512021A
(ja)
|
1994-04-19 |
1997-12-02 |
ザ ユニバーシティ オブ カンサス |
Ｉｃａｍ−１／ｌｆａ−１ 短鎖ペプチドおよび該ペプチドの使用方法
|
|
US5585359A
(en)
*
|
1994-09-29 |
1996-12-17 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
|
ATE170179T1
(de)
*
|
1994-11-02 |
1998-09-15 |
Merck Patent Gmbh |
Adhäsionsrezeptor-antagonisten
|
|
US5747035A
(en)
*
|
1995-04-14 |
1998-05-05 |
Genentech, Inc. |
Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
|
|
EP0842209B1
(en)
|
1995-07-28 |
2006-10-11 |
Genzyme Corporation |
Multiblock biodegradable hydrogels for use as controlled release agents for drugs and tissue treatment agents
|
|
WO1998023608A1
(en)
*
|
1996-11-27 |
1998-06-04 |
Dupont Pharmaceuticals Company |
Novel integrin receptor antagonists
|
|
NZ502872A
(en)
|
1997-08-28 |
2002-10-25 |
Novartis Ag |
Mevinolin and compaction as LFA-1 antagonists for treating autoimmune diseases
|
|
US6541606B2
(en)
*
|
1997-12-31 |
2003-04-01 |
Altus Biologics Inc. |
Stabilized protein crystals formulations containing them and methods of making them
|
|
WO1999049856A2
(en)
|
1998-03-27 |
1999-10-07 |
Genentech, Inc. |
Antagonists for treatment of cd11/cd18 adhesion receptor mediated disorders
|
|
US6331640B1
(en)
|
1998-10-13 |
2001-12-18 |
Hoffmann-La Roche Inc. |
Diaminopropionic acid derivatives
|
|
US6670321B1
(en)
*
|
1998-12-30 |
2003-12-30 |
The Children's Medical Center Corporation |
Prevention and treatment for retinal ischemia and edema
|
|
ATE330631T1
(de)
*
|
1999-01-05 |
2006-07-15 |
Univ Southern Australia |
Antikörperfragmente zur lokalen behandlung von augenerkrankungen
|
|
EP1028114A1
(en)
*
|
1999-02-13 |
2000-08-16 |
Aventis Pharma Deutschland GmbH |
Novel guanidine derivatives as inhibitors of cell adhesion
|
|
US6294522B1
(en)
*
|
1999-12-03 |
2001-09-25 |
Cv Therapeutics, Inc. |
N6 heterocyclic 8-modified adenosine derivatives
|
|
US6605597B1
(en)
*
|
1999-12-03 |
2003-08-12 |
Cv Therapeutics, Inc. |
Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
|
|
PT1237575E
(pt)
*
|
1999-12-14 |
2008-11-17 |
Genentech Inc |
Antagonista de tnf-alfa e antagonista de lfa-1 para tratar a artrite reumatóide
|
|
ATE294188T1
(de)
|
2000-01-14 |
2005-05-15 |
Richard S Larson |
Peptidische inhibitoren der lfa-1/icam-1 interaktion
|
|
US6515124B2
(en)
|
2000-02-09 |
2003-02-04 |
Hoffman-La Roche Inc. |
Dehydroamino acids
|
|
EP1296943A1
(fr)
*
|
2000-05-05 |
2003-04-02 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) |
Derives d'aminoacides et leur application a titre de medicaments
|
|
CN1705649A
(zh)
*
|
2000-06-29 |
2005-12-07 |
艾伯特公司 |
芳基苯基杂环基硫醚衍生物及其作为抑制细胞粘附的抗炎和免疫抑制剂的用途
|
|
PE20020420A1
(es)
*
|
2000-10-02 |
2002-06-27 |
Novartis Ag |
Derivados de diazacicloalcanodiona como antagonistas del antigeno asociado a la funcion del linfocito-1 (lfa-1)
|
|
US6653478B2
(en)
*
|
2000-10-27 |
2003-11-25 |
Ortho-Mcneil Pharmaceutical, Inc. |
Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators
|
|
GB0028367D0
(en)
*
|
2000-11-21 |
2001-01-03 |
Celltech Chiroscience Ltd |
Chemical compounds
|
|
US6667318B2
(en)
*
|
2000-11-28 |
2003-12-23 |
Genentech, Inc. |
LFA-1 antagonist compounds
|
|
ES2275808T3
(es)
*
|
2001-02-06 |
2007-06-16 |
Pfizer Products Inc. |
Composiciones farmaceuticas para el tratamiento de trastornos del snc y otros trastornos.
|
|
WO2002098370A2
(en)
*
|
2001-03-02 |
2002-12-12 |
Medimmune, Inc. |
Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
|
|
US6391290B1
(en)
*
|
2001-03-21 |
2002-05-21 |
Schering-Plough Healthcare Products, Inc. |
Skin care compositions
|
|
US6872382B1
(en)
*
|
2001-05-21 |
2005-03-29 |
Alcon, Inc. |
Use of selective PDE IV inhibitors to treat dry eye disorders
|
|
ATE383858T1
(de)
*
|
2001-06-06 |
2008-02-15 |
Aventis Pharma Ltd |
Substituierte tetrhydroisochinolin-derivate zur behandlung von entzündlichen erkrankungen
|
|
WO2003009740A2
(en)
*
|
2001-07-24 |
2003-02-06 |
Biogen Idec Ma Inc. |
Methods for treating or preventing sclerotic disorders using cd2-binding agents
|
|
RU26988U1
(ru)
|
2002-05-06 |
2003-01-10 |
Закрытое акционерное общество "ДУКС-ЛИЗИНГ" |
Кондуктор для сверления отверстий
|
|
AU2003248627A1
(en)
*
|
2002-06-06 |
2003-12-22 |
Dana-Farber Cancer Institute |
Compounds or agents that inhibit and induce the formation of focal microvessel dilatations
|
|
US7785578B2
(en)
*
|
2002-10-11 |
2010-08-31 |
Aciont, Inc. |
Non-invasive ocular drug delivery
|
|
JP5105578B2
(ja)
*
|
2003-11-05 |
2012-12-26 |
サーコード バイオサイエンス インコーポレイテッド |
細胞接着のモジュレーター
|
|
SI1682537T1
(sl)
*
|
2003-11-05 |
2012-08-31 |
Sarcode Bioscience Inc |
Modulatorji celularne adhezije
|
|
WO2005065668A2
(en)
*
|
2003-12-29 |
2005-07-21 |
Qlt Usa, Inc. |
Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders
|
|
WO2005123777A2
(en)
*
|
2004-06-09 |
2005-12-29 |
Genentech, Inc. |
Method of treating granuloma annulare or sarcoid
|
|
MX2007000851A
(es)
*
|
2004-07-22 |
2007-03-26 |
Wyeth Corp |
Procedimiento para el tratamiento de trastornos y dolencias del sistema nervioso.
|
|
US8168655B2
(en)
*
|
2005-05-17 |
2012-05-01 |
Sarcode Bioscience Inc. |
Compositions and methods for treatment of eye disorders
|
|
MX2010004281A
(es)
*
|
2007-10-19 |
2010-09-10 |
Sarcode Corp |
Composiciones y metodos para el tratamiento de la retinopatia diabetica.
|
|
WO2009139817A2
(en)
*
|
2008-04-15 |
2009-11-19 |
Sarcode Corporation |
Crystalline pharmaceutical and methods of preparation and use thereof
|
|
JP2011516607A
(ja)
*
|
2008-04-15 |
2011-05-26 |
サーコード コーポレイション |
胃腸系へのｌｆａ−１アンタゴニストの送達
|
|
EP2265124A4
(en)
*
|
2008-04-15 |
2011-12-28 |
Sarcode Bioscience Inc |
AEROSOLISED LFA-1 ANTAGONISTS FOR THE USE IN THE LOCAL TREATMENT OF IMMUNE DISEASES
|
|
US8378105B2
(en)
*
|
2009-10-21 |
2013-02-19 |
Sarcode Bioscience Inc. |
Crystalline pharmaceutical and methods of preparation and use thereof
|
|
SI3715345T1
(sl)
*
|
2012-07-25 |
2024-07-31 |
Bausch + Lomb Ireland Limited |
Priprava zaviralca lfa-1
|